StockNews.com upgraded shares of Tactile Systems Technology (NASDAQ:TCMD – Free Report) from a buy rating to a strong-buy rating in a research report sent to investors on Friday.
Other analysts have also recently issued reports about the company. B. Riley assumed coverage on Tactile Systems Technology in a research note on Thursday, September 26th. They issued a “buy” rating and a $23.00 price target on the stock. BTIG Research lowered Tactile Systems Technology from a “buy” rating to a “neutral” rating in a research report on Tuesday, November 5th. Finally, Oppenheimer downgraded Tactile Systems Technology from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 5th.
Check Out Our Latest Analysis on Tactile Systems Technology
Tactile Systems Technology Stock Performance
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in the company. Arcadia Investment Management Corp MI purchased a new position in Tactile Systems Technology during the 3rd quarter worth $29,000. Gladius Capital Management LP purchased a new position in shares of Tactile Systems Technology during the third quarter worth about $44,000. Quarry LP acquired a new position in Tactile Systems Technology in the 2nd quarter valued at about $46,000. Magnetar Financial LLC acquired a new position in Tactile Systems Technology in the 2nd quarter valued at about $130,000. Finally, SG Americas Securities LLC purchased a new stake in Tactile Systems Technology during the 3rd quarter valued at approximately $156,000. Hedge funds and other institutional investors own 83.43% of the company’s stock.
Tactile Systems Technology Company Profile
Tactile Systems Technology, Inc, a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers.
Further Reading
- Five stocks we like better than Tactile Systems Technology
- Low PE Growth Stocks: Unlocking Investment Opportunities
- XPO Stock Gains Momentum as U.S. Trade Outlook Evolves
- Top Biotech Stocks: Exploring Innovation Opportunities
- CarMax Gets in Gear: Is Now the Time to Buy?
- How to Use the MarketBeat Stock Screener
- Qubit Combat: 2 Stocks Battle for Quantum Supremacy
Receive News & Ratings for Tactile Systems Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tactile Systems Technology and related companies with MarketBeat.com's FREE daily email newsletter.